Table 2.
Clinical characteristics of CD subjects stratified by global MRI positivity
| Variable | Global MRI positive (N = 4, 12.1%) |
Global MRI negative (N = 29, 87.9%) |
p-value |
|---|---|---|---|
| Demographics | |||
| Age | 51.2 ± 12.5 | 37.2 ± 12.9 | 0.04 |
| Female gender | 2 / 4 (50.0%) | 23 / 29 (79.3%) | 0.24 |
| Tobacco use | 2 / 4 (50.0%) | 4 / 28 (14.3%) | 0.15 |
| ASAS Clinical Arm Variables | |||
| Inflammatory back pain | 4 / 4 (100.0%) | 15 / 29 (51.7%) | 0.12 |
| Peripheral arthritis (current) | 3 / 4 (75.0%) | 15 / 29 (51.7%) | 0.60 |
| Peripheral arthritis (history) | 4 / 4 (100.0%) | 18 / 29 (62.1%) | 0.28 |
| Current enthesitis | 2 / 8 (25.0%) | 8 / 29 (27.6%) | 0.99 |
| History of uveitis | 1 / 4 (25.0%) | 3 / 29 (10.3%) | 0.42 |
| History of dactylitis | 2 / 4 (50.0%) | 1 / 29 (3.4%) | 0.03 |
| HLA-B27** | 0 / 4 (0.0%) | 1 / 29 (3.4%) | 0.99 |
| CRP | 2.6 ± 3.0 | 1.5 ± 2.6 | 0.43 |
| SpA Related Variables | |||
| BASDAI | 4.3 ± 1.7 | 4.2 ± 2.4 | 0.92 |
| BASMI | 4.1 ± 0.7 | 2.4 ± 0.8 | <0.001 |
| ASDAS-CRP | 3.3 ± 0.4 | 2.5 ± 1.2 | 0.19 |
| Crohn’s Disease Variables | |||
| Duration of disease | 17.9 ± 3.8 | 12.2 ± 8.7 | 0.20 |
| HBI Score | 7.8 ± 4.9 | 8.3 ± 4.5 | 0.83 |
| Vedolizumab use | 0 / 4 (0.0%) | 7 / 28 (25.0%) | 0.55 |
| Prior history of biologic use | 3 / 4 (75.0%) | 16 / 28 (57.1%) | 0.63 |
| Surgery related to CD | 3 / 4 (75.0%) | 16 / 28 (57.1%) | 0.99 |
**
HLA-B27 missing in 2 subjects
ASAS=Assessment of SpondyloArthritis international Society, ASDAS-CRP= Ankylosing Spondylitis Disease Activity Score C-reactive protein, BASDAI = Bath Ankylosing Spondylitis Activity Index, BASMI = Bath Ankylosing Spondylitis Metrology Index, CD= Crohn’s disease, CRP= C-reactive protein, HBI= Harvey Bradshaw Index, HLA-B27= Human Leukocyte Antigen B-27